| P287 | HyPeR: A phase 1, dose escalation study of Guadecitabine (SGI-110) a second generation hypomethylating agent in combination with Pembrolizumab (MK3475) in patients with refractory solid tumours | Malaka Ameratunga, MBBS; Maxime Chénard-Poirier; Sanjena Mithra; Ricardo Morilla; Ruth Riisnaes; Penny Flohr; Rita Pereira, BSc; Ana Ferreira, MSc; Ines Figueiredo; Suzanne Carreira; Claudia Bertan; Wei Yuan; David Dolling; Mateus Crespo; Bora Gurel; Bob Brown; Naina Patel; Joanna Dawes; Toby Prout; Mona Parmar; Alison Turner; Holly Tovey; Emma Hall; Anna Minchom; Udai Banerji; Nina Tunariu; Juanita Lopez; Dionysis Papadatos-Pastos; Johann S. De Bono, MD; | Checkpoint blockade; Clinical study; Clinical trial |
| P288 | IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. | Angus G. Dalgleish, MD, PhD; | Chemotherapy; Clinical trial; Costimulation; Immune suppression; NK/NK T cell; Solid tumors; TLR; Tumor microenvironment |
| P289 | Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors | Sunil Sharma, MD; Kathleen N. Moore; Niharika B. Mettu; Ignacio Garrido-Laguna; Susanna V. Ulahannan, MD, MMed; Vivek Khemka, MD; Ann Kapoun; Leonardo Faoro; Johanna Bendell, MD | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| P290 | Immunologic biomarkers in a multi-center, single arm, open label Phase II clinical trial of mFOLFOX6 and pembrolizumab in patients with advanced colorectal cancer | Matthew R. Farren, Ph.D.; Yan Tong; Ziuye Liu; Bert O'Neil; Tanios Bekaii-Saab, MD; Anne Noonan; Christopher W. McQuinn, MD; Thomas Mace, PhD; Walid L. Shaib, MD; Christina Wu, MD; Bassel El-rayes, MD; Safi Shahda, MD; Gregory B. Lesinski, PhD, MPH; Matthew R. Farren, Ph.D. | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Solid tumors |
| P291 | A targeted modified IL-2 (NHS-IL2) combined with stereotactic body radiation therapy (SBRT) in patients with advanced melanoma refractory to checkpoint inhibitors: Results from a Phase IIa trial | Omid Hamid, MD; David H. Lawson, MD; Karl D. Lewis, MD; Jose Lutzky, MD, FACP; C. Lance Cowey; Beatrice Brunkhorst; Meng Li; Wanping Geng; Christine Hicking; Vijay Kasturi, MD; Howard Kaufman | Antibody; Biomarkers; Clinical study; Clinical trial; Cytokine; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors |
| P292 | Changes in intra- and perinodular heterogeneity patterns on serial computed tomography are associated with overall survival in Nivolumab-treated non-small cell lung cancer | Mohammadhadi Khorrami, PhD; Prateek Prasanna, PhD; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, PhD; | Biomarkers; Immune monitoring; Solid tumors; Tumor microenvironment |
| P293 | Autologous tumor cell vaccination combined with systemic CpG-B and IFNα promotes activation of dendritic cells and T cells and induces clinical responses in metastatic Renal Cell Carcinoma | Bas D. Koster, MD; Saskia Santegoets; Jorien J. Harting, MD; Arnold Baars, MD, PhD; Marieke van Ham, PhD; Rik J. Scheper, PhD; Erik Hooijberg, PhD; Alfons JM. van den Eertwegh, MD, PhD; Tanja D. de Gruijl, PhD | Clinical study; Clinical trial; Dendritic cell; Immune adjuvant; Immune monitoring; Solid tumors; T cell; TLR |
| P294 | Confirmatory study validates a MALDI prognostic signature for IL-2 response and the adverse prognostic role of the serum apoptotic marker Hepatocyte Growth Factor (HGF) in Renal Cell Carcinoma (RCC) | Michael T. Lotze, MD; Shuyan Zhai, PhD; Daniel P. Normolle, PhD; Ryan J. Sullivan, MD; Heinrich Roder, DPhil; Joanna Roder, PhD; David F. McDermott, MD; Theodore F. Logan, MD; Marc S. Ernstoff, MD; Thomas Olencki, DO; David Friedland, MD; Rahul A. Parikh, MD, PhD; Jodi K. Maranchie, MD; Mary Jo Buffo, BS; Lisa H. Butterfield, PhD; Leonard J. Appleman, MD, PhD; | Clinical study; Clinical trial; Cytokine; Immune contexture; Solid tumors |
| P295 | A Phase 1, open-label, multicenter, dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies | Shilpa G. Gupta, MD; Todd M. Bauer, MD; Ryan J. Sullivan, MD; Robert H. Andtbacka, MD, CM, FACS, FRCSC; Ding Wang, MD; Geoffrey Shapiro, MD, PhD; Khanh T. Do, MD; Kurt A. Schalper, MD, PhD; Patricia Gaule, PhD; Tal Zaks, MD, PhD; Joshua Frederick, PhD; Lisa Johansen; Kristen Hopson, PhD; William Randolph; Sima Zacharek, PhD; Robert S. Meehan, MD; Antonio Jimeno, MD, PhD; | Biomarkers; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P297 | Systemic activation and polyclonal expansion of CD8 T cells in cancer patients on Pegilodecakin alone or in combination with anti-PD-1 | Aung Naing, MD, FACP; Jeffrey R. Infante, MD; Kyri P. Papadopoulos; Ivan Chan, PhD; Cong Shen; Navneet Ratti, BS, MBA; Bianca Rojo, MSc; Karen Autio, MS, MD; Deborah J. Wong, MD PhD; Manish R. Patel, MD; Patrick A. Ott, MD, PhD; Gerald S. Falchook, MD; Shubham Pant, MBBS; Annie Hung, BA; John B. Mumm, PhD; Matthew Adamow; Scott McCauley, BA; Phillip Wong, PhD; Peter Van Vlasselaer, PhD; Joseph Leveque; Edward B. Garon, MD; Nizar M. Tannir, MD, FACP; Martin Oft, MD; Martin Oft, MD; | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; T cell |
| P298 | T cell response induced by the addition of IL-7 treatment following sipuleucel-T immunotherapy in metastatic castration resistant-prostate cancer | Russell Pachynski, MD; Russell Szmulewitz, MD; Lauren Harshman, MD; Leonard J. Appleman, MD, PhD; Paul Monk, MD; Rhonda Bitting; Omer Kucuk, MD; Frederick Millard, MD; John Seigna; Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Bruce Hess, BS; Leonard D'Amico, PhD; Andreanne M. Lacroix, BS; Judith C. Kaiser, MBA, BSN, RN; Michel Morre, DVM, MSc.; Anne GREGOIRE, phD; Martin A. Cheever, MD; Evan Y. Yu, MD; Lawrence Fong, MD | Adoptive immunotherapy; Antigen presenting cells; Clinical trial; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; T cell |
| P299 | Combination of subcutaneously administered TLR9 agonist lefitolimod with CTLA-4 checkpoint inhibitor ipilimumab - A phase I trial in patients with advanced solid tumors | Matthew J. Reilley, MD; Casey Ager, BS; Martin Meng; Apostolia M. Tsimberidou, MD, PhD; Sarina A. Piha-Paul, MD; Timothy A. Yap, MD; Siqing Fu, MD, PhD; Aung Naing, MD, FACP; Jordi Rodon; Ly Nguyen; Priya Bhosale, MD; Manuel Schmidt, MSc; Matthias Baumann; Funda Meric-Bernstam, MD; Michael A. Curran, PhD; David Hong, MD | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; T cell; T cell lineages; TLR; Tumor microenvironment |
| P300 | First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors | Kohei Shitara, MD; Satoshi ueha; Shigeyuki Shichino; Hiroyasu Aoki; Haru Ogiwara, M.D., Ph.D.; Tetsuya Nakatsura; Toshihiro Suzuki; Manami Shimomura; Toshiaki Yoshikawa; Kayoko Shoda; Shigehisa Kitano; Makiko Yamashita; Takayuki Nakayama; Akihiro Sato; Sakiko Kuroda; Masashi Wakabayashi; Shogo Nomura; Satoru Ito; Kouji Matsushima; Toshihiko Doi, MD, PhD | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; T cell; Targeted therapy |
| P301 | MLH1/ MSH2 expression and the prognosis of colorectal cancer in 978 Chinese patients | Yu Wang, MD; shuiming wang; youping deng | Surgery |
| P302 | Phase II trial of reirradiation (ReRT) plus Pembrolizumab for locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (SCCHN): Analysis of early toxicity | Dan P. Zandberg, MD; Tejan Diwanji, MD; Robert Morales, MD; Tiffani Tyer; James Snider, MD; Alexander Engelman, MD; Soren M. Bentzen, PhD; Thomas DeMora, MD; Robert Malyapa, MD; Navid Saeidi; Ana Ponce Kiess, MD; Josh Lubek, MD; Robert Ord, MD; Donita Dyalram, MD; Kyle Hatten, MD; Jeffrey S. Wolf, MD; rodney Taylor, MD; John Papadimitriou, MD, PhD; Ranee Mehra, MD; Harry Quon, MD; Hyunseok Kang, MD, MPH; John A. Ridge, MD, PhD; Jessica Bauman, MD; William F. Regine, MD; Mohan Suntharalingam, MD; Scott E. Strome, MD; Kevin Cullen, MD; | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| O19 | Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors | Dmitriy Zamarin, MD, PhD; Omid Hamid, MD; Asha Nayak, MD; Solmaz Sahebjam, MD; Mario Sznol, MD; Agron Collaku, PhD; Floyd E. Fox, PhD; Margaret A. Marshall, MD; David Hong, MD; | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
